Aureus Pharma Extends Agreement With Sanofi-Aventis

Published: 05-Nov-2009

To provide new AurSCOPE knowledge databases and continue to update existing databases for sanofi-aventis’ R&D division

Aureus Pharma has extended its knowledge database agreement with sanofi-aventis research & development for an additional three-year term. Under the agreement, Aureus will provide new AurSCOPE knowledge databases and continue to update existing databases for sanofi-aventis’ R&D division.

The Aureus Pharma databases will give sanofi-aventis researchers access to information on major therapeutic targets. These include GPCR protein receptors, nuclear receptors, kinase inhibitors, ion channels, as well as information relative to drug safety including data on ADME (absorption, distribution, metabolism, and excretion).

The new agreement reinforces the relationship between Aureus Pharma and sanofi-aventis, which has been in existence for seven years already. It also secures additional revenues for Aureus over the next three years.

Jason Theodosiou, CEO of Aureus Pharma, said: “Sanofi-aventis’ decision to extend the partnership for an additional three year period, as well as to acquire new knowledge bases, confirms the fact that Aureus’ products are meeting the needs of the world’s leading pharmaceutical companies.”

Tell your friend about this article